NAD⁺ is having its moment. Whether it deserves the moment is a fair question — and the answer depends almost entirely on how it's prescribed, not whether it works.
Nicotinamide adenine dinucleotide (NAD⁺) is a coenzyme present in every cell of your body. It's the molecular handshake that drives oxidative phosphorylation in your mitochondria, activates the sirtuin family of longevity genes, fuels the DNA-repair enzyme PARP-1, and regulates dozens of metabolic switches that quietly fail with age.
Cellular NAD⁺ levels decline measurably across the lifespan. By the seventh decade, levels in most tissues are roughly half of what they were in early adulthood. That decline is correlated with mitochondrial dysfunction, metabolic slowdown, neurodegeneration, and the broad cluster of complaints we lump under "aging."
NAD⁺ depletion is one of the few cellular changes that maps cleanly onto multiple hallmarks of aging — and one of the few that can be measurably reversed.
— Verdin, Science (2015)
Pill, patch, push, or drip — these are not equivalent
NAD⁺ supplementation has become a category, not a treatment. The market includes oral precursors (NMN, NR), sublingual lozenges, transdermal patches, IM injections, slow IV infusions, and at-home subcutaneous protocols. They are not interchangeable. The bioavailability gap between the cheapest and most clinically useful is roughly two orders of magnitude.
| Effective dose to cells | Clinical use case | |
|---|---|---|
| Oral NMN / NR | Low — extensive first-pass metabolism | Daily maintenance, long-term floor |
| Sublingual / patch | Low to moderate — variable absorption | Convenience-tier supplementation |
| IM injection | Moderate — bypasses gut, peaks fast | Short-burst use, performance contexts |
| Slow IV infusion | High — direct into systemic circulation | Clinical arcs, recovery, cognitive |
Why slow matters more than dose
The most common patient complaint about NAD⁺ IVs is the side-effect profile of a fast push: chest pressure, jaw tightness, intense flushing, GI cramping. None of those are dangerous. All of them are entirely a function of infusion rate.
At BioHaus, our standard NAD⁺ infusions run between 90 minutes and 4 hours depending on dose and tolerance. We start every member at a conservative rate, titrate upward across sessions, and pair the infusion with a methyl-donor stack (B-complex, methylated folate, glutathione) to protect the methylation cycle that NAD⁺ metabolism draws from.
| Why it's there | |
|---|---|
| NAD⁺ (250–1000 mg) | The active substrate. Dose calibrated to weight, prior tolerance, and goal. |
| Glutathione push | Master antioxidant. Protects against the oxidative load of high-dose NAD⁺ flux. |
| Methylated B-complex | Supports the methylation cycle that NAD⁺ pathways draw on heavily. |
| Magnesium | Cofactor for >300 enzymes; reduces vasoconstrictive symptoms during infusion. |
| Saline carrier | Hydration matters more than wellness clinics admit. Cellular delivery scales with volume. |
What members actually feel
The honest answer is that NAD⁺ does not produce a same-day "high." The clinically meaningful effects emerge across a clustered arc, typically 6–10 infusions delivered across 4–6 weeks, and they show up first in sleep architecture, then in baseline energy, then — sometimes — in measurable cognitive metrics on a follow-up qEEG. Members in active recovery from a metabolic insult or long-COVID feel it sooner. Members using NAD⁺ as a longevity floor feel it more subtly.
A clinical IV is not a menu item. It's a prescription with an infusion rate.
The contraindications worth knowing
NAD⁺ should be screened with care in active malignancy, advanced kidney disease, and pregnancy. It draws meaningfully on methyl donors, which is why we run methylation panels on members considering long arcs. None of this is a reason to avoid NAD⁺. It's a reason to insist that the person prescribing it has actually looked at your labs.
